https://www.marketscreener.com/quote/stock/LYELL-IMMUNOPHARMA-INC-123776313/news/SITC-2023-Epi-R-P2-protocol-produces-a-scalable-polyclonal-TIL-product-with-a-greater-expansion-suc-45238944/?utm_source=telegram&utm_medium=social&utm_campaign=share